Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2016

Kwiatkowski David J, Choueiri Toni K, Fay André P, Rini Brian I, Thorner Aaron R, de Velasco Guillermo, Tyburczy Magdalena E, Hamieh Lana, Albiges Laurence, Agarwal Neeraj, Ho Thai H, Song Jiaxi, Pignon Jean-Christophe, Barrios Pablo M, Michaelson M Dror, Van Allen Eliezer, Krajewski Katherine M, Porta Camillo, Pal Sumanta, Bellmunt Joaquim, McDermott David F, Heng Daniel Y C, Gray Kathryn P, Signoretti Sabina

Abstract excerpt

PURPOSE: We examined the hypothesis that mutations in mTOR pathway genes are associated with response to rapalogs in metastatic renal cell carcinoma (mRCC). EXPERIMENTAL DESIGN: We studied a cohort of mRCC patients who were treated with mTOR inhibitors with distinct clinical outcomes. Tumor DNA from 79 subjects was successfully analyzed for mutations using targeted next-generation sequencing of 560 cancer genes....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Kidney Neoplasms

Share to Protein Kinase Inhibitors

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis Complex 1 Protein

Share to Tuberous Sclerosis Complex 2 Protein

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26831717
DOI: 10.1158/1078-0432.CCR-15-2631
PMCID: PMC4976069

Genes

TSC1
TSC2
MTOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.PMID 26831717Read ↗

Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.Semantic proximity Read ↗

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinomaSemantic proximity Read ↗

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.Semantic proximity Read ↗

Enhancing mTOR-targeted cancer therapySemantic proximity Read ↗

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapySemantic proximity Read ↗

PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.Semantic proximity Read ↗

Unconventional mechanism of action and resistance to rapalogs in renal cancer.Semantic proximity Read ↗

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.Semantic proximity Read ↗

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.Semantic proximity Read ↗

Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.Semantic proximity Read ↗

Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors.Semantic proximity Read ↗

Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.